The efficacy and safety of Silymarin in chemotherapy-induced peripheral neuropathy (CIPN)
Phase 2
Recruiting
- Conditions
- Chemotherapy induced peripheral neuropathy in confirmed diagnosed cancer patients..Serum neuropathyG61.1
- Registration Number
- IRCT20201128049515N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Histologically confirmed diagnosis of cancer
At least 18 years of age
Having chemotherapy-induced peripheral neuropathy (CIPN).
Exclusion Criteria
Having a known disease predisposing to neuropathy, including diabetes, neuromuscular disease, vitamin B12 deficiency, amyloidosis, and connective tissue disease, a history of neurological diseases such as hereditary and acquired neuropathies
Unbearable side effects of the drug or drug reaction
Taking any antioxidant supplement in the last two months
Pregnancy, or breastfeeding
unwillingness to attend the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method europathy intensity. Timepoint: The first day and 3rd month after the onset of the intervention. Method of measurement: Common Terminology Criteria for Adverse Events (CTCAE) criterion and questionnaire.
- Secondary Outcome Measures
Name Time Method Quality of life. Timepoint: The first day and the 3rd month after the start of the intervention. Method of measurement: European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ).;Pain intensity. Timepoint: The first day and 3rd month after the start of the intervention. Method of measurement: Visual analysis scale (VAS) criterion and questionnaire.